Adelaide Research & Scholarship: Search

Search

Results 21-30 of 53 (Search time: 0.003 seconds).

previous
1
2
3
4
5
6
next

Item hits:

Preview	Issue Date	Title	Author(s)
	1997	Detection of minimal residual disease in an AML patient with trisomy 8 using interphase fish	White, D.; Hutchins, C.; Turczynowicz, S.; Suttle, J.; Haylock, D.; Hughes, T.; Juttner, C.; To, L.
	2013	Proton pump inhibitors significantly increase the intracellular concentration of nilotinib, but not imatinib in target CML cells	White, D.; Eadie, L.; Saunders, V.; Hiwase, D.; Hughes, T.
	2010	Nilotinib-mediated inhibition of ABCB1 increases intracellular concentration of dasatinib in CML cells: implications for combination TKI therapy	Hiwase, D.; White, D.; Zrim, S.; Saunders, V.; Vaz de Melo, J.; Hughes, T.
	2010	Chronic Myeloid Leukemia CD34+ cells have reduced uptake of imatinib due to low OCT-1 Activity	Engler, J.; Frede, A.; Saunders, V.; Zannettino, A.; Hughes, T.; White, D.
	2013	NPM1 mutations occur rarely or not at all in chronic myeloid leukaemia patients in chronic phase or blast crisis	Watkins, D.; Hughes, T.; White, D.; D'Andrea, R.
	2011	OCT-1 as a determinant of response to antileukemic treatment	Engler, J.; Hughes, T.; White, D.
	2013	Low GFI1 expression in white blood cells of CP-CML patients at diagnosis is strongly associated with subsequent blastic transformation	Kok, C.; Watkins, D.; Leclercq, T.; D'Andrea, R.; Hughes, T.; White, D.
	2008	BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros	Mullighan, C.; Miller, C.; Radtke, I.; Philips, L.; Dalton, J.; Ma, J.; White, D.; Hughes, T.; Le Beau, M.; Pui, C.; Relling, M.; Shurtleff, S.; Downing, J.
	2010	Blocking cytokine signaling along with intense Bcr-Abl kinase inhibition induces apoptosis in primary CML progenitors	Hiwase, D.; White, D.; Powell, J.; Saunders, V.; Zrim, S.; Frede, A.; Guthridge, M.; Lopez, A.; D'Andrea, R.; To, L.; Vaz de Melo, J.; Kumar, S.; Hughes, T.
	2003	Successful peripheral blood stem cell mobilisation with filgrastim in patients with chronic myeloid leukaemia achieving complete cytogenetic response with imatinib, without increasing disease burden as measured by quantitative real-time PCR	Hui, C.; Goh, K.; White, D.; Branford, S.; Grigg, A.; Seymour, J.; Kwan, Y.; Walsh, S.; Hoyt, R.; Trickett, A.; Rudzki, Z.; Ma, D.; To, L.; Hughes, T.